Multivesicular Liposome (Depofoam) in Human Diseases

• Published in: Iranian journal of pharmaceutical research : IJPR 2020-01, Vol.19 (2), p.9-21
• Main Authors: Salehi, Bahare, Mishra, Abhay P, Nigam, Manisha, Kobarfard, Farzad, Javed, Zeeshan, Rajabi, Sadegh, Khan, Khushbukhat, Ashfaq, Hafiz Ahsan, Ahmad, Toqeer, Pezzani, Raffaele, Ramírez-Alarcón, Karina, Martorell, Miquel, Cho, William C, Ayatollahi, Seyed Abdulmajid, Sharifi-Rad, Javad
• Format: Article
• Language: English
• Subjects: Review
• ISSN: 1735-0328; 1726-6890
• DOI: 10.22037/ijpr.2020.112291.13663

Drug development is a key point in the research of new therapeutic treatments for increasing maximum drug loading and prolonged drug effect. Encapsulation of drugs into multivesicular liposomes (DepoFoam) is a nanotechnology that allow delivery of the active constituent at a sufficient concentration during the entire treatment period. This guarantees the reduction of drug administration frequency, a very important factor in a prolonged treatment. Currently, diverse DepoFoam drugs are approved for clinical use against neurological diseases and for post-surgical pain management while other are under development for reducing surgical bleeding and for post-surgical analgesia. Also, on pre-clinical trials on cancer DepoFoam can improve bioavailability and stability of the drug molecules minimizing side effects by site-specific targeted delivery. In the current work, available literature on structure, preparation and pharmacokinetics of DepoFoam are reviewed. Moreover, we investigated approved DepoFoam formulations and preclinical studies with this nanotechnology.